Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer

Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance therapy

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that new real-world evidence evaluating whole-genome sequencing-based homologous recombination deficiency phenotyping has been accepted for online publication at the 2026 American Society of Clinical Oncology Annual Meeting.

The abstract, titled “Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer,” reports findings from a collaborative study between Inocras and the Severance Hospital gynecologic oncology team, one of Inocras’s major clinical partners in Korea.

Using matched tumor-normal whole-genome sequencing through CancerVision, investigators evaluated 84 patients with high-grade serous ovarian cancer who received PARP inhibitor maintenance therapy in either the first-line or second-line maintenance setting. The study assessed whether WGS-based HRD indicators, or CancerVision’s WGS-HRD, correlated with clinical outcomes following PARP inhibitor therapy.

Patients classified as WGS-HRD-positive had a longer median progression-free survival than those classified as WGS-HRD-negative, with an overall mPFS of 27.5 months versus 12.0 months. The association was most pronounced in the first-line maintenance setting, where WGS-HRD positive patients had an mPFS of 44.2 months versus 10.0 months. In the second-line maintenance setting, no significant difference in survival was observed based on HRD status, suggesting the predictive value of WGS-HRD may be strongest in earlier treatment settings.

The study also found that 21.4% of patients were WGS-HRD positive despite lacking BRCA mutations, underscoring the potential of WGS-HRD to identify patients who may not be captured by BRCA testing alone. Compared with the conventional scarHRD method, WGS-HRD demonstrated higher predictive value in clinical prognosis and PARP inhibitor responsiveness. The study adds to Inocras’ growing body of evidence supporting CancerVision as a comprehensive whole-genome sequencing platform for precision oncology.

“These findings provide important real-world evidence that whole-genome HRD scoring can advance how we identify ovarian cancer patients most likely to benefit from PARP inhibitor maintenance therapy,” said Jehee Suh, CEO of Inocras. “CancerVision is a comprehensive WGS-based clinical analysis platform, and these data highlight its potential to enhance clinical decision-making.”

“The first-line maintenance findings are particularly encouraging because they suggest that WGS-based HRD assessment may refine current BRCA- and genomic-scar–based approaches for identifying patients most likely to derive durable benefit from PARP inhibitor maintenance therapy,” said Joonoh Lim, Physician Scientist at Inocras, who led the study in collaboration with Severance Hospital. “These findings add to the growing evidence base for whole-genome HRD assessment, and we look forward to prospective validation.”

Abstract Details

Title: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer.
Format: Online publication / Online-only abstract
Abstract Number: e17608
Publication Date/Time: May 21 at 05:00 PM ET
Authors: Joonoh Lim, MD, PhD, Inocras Inc., San Diego, CA
Session/Category: Gynecologic Cancer

About CancerVision

CancerVision is Inocras’ whole-genome sequencing-based precision oncology platform designed to provide comprehensive genomic insights from matched tumor-normal analysis. By integrating genome-wide biomarkers, CancerVision supports clinical research and decision-making across cancer types, including applications in homologous recombination deficiency assessment.

About Inocras

Inocras is a bioinformatics-led company redefining precision health through whole genome data and proprietary analytics. Our oncology and rare disease platforms integrate comprehensive whole genome data with advanced automation to deliver curated and actionable insights at scale that accelerate discovery and diagnostics to improve patient care, bringing a real-world impact. Inocras operates a CLIA/CAP-certified laboratory and partners with leading hospitals, pharmaceutical companies, and research institutions worldwide. For more information, please visit inocras.com and follow the Inocras LinkedIn page.